CN110691512A - 遗传工程化的非人类哺乳动物及其构建方法和应用 - Google Patents
遗传工程化的非人类哺乳动物及其构建方法和应用 Download PDFInfo
- Publication number
- CN110691512A CN110691512A CN201880028071.9A CN201880028071A CN110691512A CN 110691512 A CN110691512 A CN 110691512A CN 201880028071 A CN201880028071 A CN 201880028071A CN 110691512 A CN110691512 A CN 110691512A
- Authority
- CN
- China
- Prior art keywords
- mice
- animal
- cell
- tissue
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000010276 construction Methods 0.000 title description 8
- 210000000056 organ Anatomy 0.000 claims abstract description 40
- 238000012216 screening Methods 0.000 claims abstract description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 56
- 102000040430 polynucleotide Human genes 0.000 claims description 56
- 239000002157 polynucleotide Substances 0.000 claims description 56
- 210000001519 tissue Anatomy 0.000 claims description 53
- 241001465754 Metazoa Species 0.000 claims description 52
- 206010020772 Hypertension Diseases 0.000 claims description 51
- 101150037123 APOE gene Proteins 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 238000003197 gene knockdown Methods 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 37
- 108091026890 Coding region Proteins 0.000 claims description 35
- 108060001084 Luciferase Proteins 0.000 claims description 30
- 239000005089 Luciferase Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 102000005862 Angiotensin II Human genes 0.000 claims description 24
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 24
- 229950006323 angiotensin ii Drugs 0.000 claims description 24
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 23
- 230000001939 inductive effect Effects 0.000 claims description 21
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 21
- 201000001320 Atherosclerosis Diseases 0.000 claims description 20
- 102000018120 Recombinases Human genes 0.000 claims description 20
- 108010091086 Recombinases Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 208000007536 Thrombosis Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 108091033409 CRISPR Proteins 0.000 claims description 14
- 102000009661 Repressor Proteins Human genes 0.000 claims description 14
- 108010034634 Repressor Proteins Proteins 0.000 claims description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims description 14
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 13
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 12
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 11
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 10
- 101001125417 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Proteins 0.000 claims description 10
- 102100029467 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Human genes 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 9
- 229940000406 drug candidate Drugs 0.000 claims description 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 8
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 230000035488 systolic blood pressure Effects 0.000 claims description 7
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 108090000331 Firefly luciferases Proteins 0.000 claims description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 230000004217 heart function Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 108010078070 scavenger receptors Proteins 0.000 claims description 6
- 102000014452 scavenger receptors Human genes 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 241000251511 Holothuroidea Species 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 230000035487 diastolic blood pressure Effects 0.000 claims description 4
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 230000008085 renal dysfunction Effects 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 206010060965 Arterial stenosis Diseases 0.000 claims description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010038366 Renal aneurysm Diseases 0.000 claims description 2
- 206010062237 Renal impairment Diseases 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 206010048214 Xanthoma Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000006866 deterioration Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000002296 eclampsia Diseases 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000005976 liver dysfunction Effects 0.000 claims description 2
- 230000003908 liver function Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000007505 plaque formation Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 230000006496 vascular abnormality Effects 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 6
- 241000965254 Apostichopus japonicus Species 0.000 claims 1
- 208000016621 Hearing disease Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 210
- 241000699666 Mus <mouse, genus> Species 0.000 description 90
- 235000009200 high fat diet Nutrition 0.000 description 80
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 229960003722 doxycycline Drugs 0.000 description 24
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 235000021590 normal diet Nutrition 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 19
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 18
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 18
- 229960000485 methotrexate Drugs 0.000 description 18
- 102000013918 Apolipoproteins E Human genes 0.000 description 15
- 108010025628 Apolipoproteins E Proteins 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 238000001514 detection method Methods 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000003902 lesion Effects 0.000 description 11
- 230000037356 lipid metabolism Effects 0.000 description 11
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 239000004098 Tetracycline Substances 0.000 description 10
- 229960002180 tetracycline Drugs 0.000 description 10
- 229930101283 tetracycline Natural products 0.000 description 10
- 235000019364 tetracycline Nutrition 0.000 description 10
- 150000003522 tetracyclines Chemical class 0.000 description 10
- 230000003143 atherosclerotic effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108010045374 CD36 Antigens Proteins 0.000 description 6
- 102000053028 CD36 Antigens Human genes 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 101100055876 Mus musculus Apoe gene Proteins 0.000 description 5
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000003209 gene knockout Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 108010024212 E-Selectin Proteins 0.000 description 4
- 108010046276 FLP recombinase Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 4
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 208000007474 aortic aneurysm Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 102100023471 E-selectin Human genes 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229940080182 methotrexate injection Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229930187593 rose bengal Natural products 0.000 description 2
- 229940081623 rose bengal Drugs 0.000 description 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100346189 Caenorhabditis elegans mpc-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101000579218 Homo sapiens Renin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000011616 hypertension animal model Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种遗传工程化的非人哺乳动物、细胞、器官和组织及其产生方法,以及所述非人哺乳动物、细胞、器官和组织在筛选或验证治疗药物中的应用。
Description
PCT国内申请,说明书已公开。
Claims (50)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710292460X | 2017-04-28 | ||
CN201710292460 | 2017-04-28 | ||
PCT/CN2018/085097 WO2018196874A1 (zh) | 2017-04-28 | 2018-04-28 | 遗传工程化的非人类哺乳动物及其构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110691512A true CN110691512A (zh) | 2020-01-14 |
CN110691512B CN110691512B (zh) | 2021-11-09 |
Family
ID=63918064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880028071.9A Active CN110691512B (zh) | 2017-04-28 | 2018-04-28 | 遗传工程化的非人类哺乳动物及其构建方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11882816B2 (zh) |
CN (1) | CN110691512B (zh) |
WO (1) | WO2018196874A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205375A (zh) * | 2019-06-26 | 2019-09-06 | 宁夏医科大学 | 一种动脉粥样硬化诊断用分子标志物及其应用 |
CN114304064A (zh) * | 2021-12-16 | 2022-04-12 | 首都医科大学 | 一种头部畸形伴神经-运动障碍动物模型的建立方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6437215B1 (en) * | 1999-06-28 | 2002-08-20 | Massachusetts Institute Of Technology | SR-BI and ApoE knockout animals and use thereof as models for atherosclerosis and heart attack |
CN1503623A (zh) * | 2001-04-10 | 2004-06-09 | 长沙惠霖干细胞工程有限公司 | 一种构建哺乳动物克隆胚的方法 |
US20050136005A1 (en) * | 1994-06-23 | 2005-06-23 | Massachusetts Institute Of Technology | Methods for modulation of cholesterol transport |
US20080075663A1 (en) * | 2006-06-20 | 2008-03-27 | The J. David Gladstone Institutes | Mouse Model of Chronic Heart Failure and Coronary Atherosclerosis Regression |
WO2012129198A1 (en) * | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
CN104677844A (zh) * | 2015-02-10 | 2015-06-03 | 浙江凯成生物科技有限公司 | 一种载脂蛋白e的定量测定方法、试剂及试剂盒 |
CN106148406A (zh) * | 2015-03-26 | 2016-11-23 | 中国农业大学 | 猪ApoE基因敲除载体及其构建方法与应用 |
CN106244556A (zh) * | 2016-08-29 | 2016-12-21 | 中国农业科学院北京畜牧兽医研究所 | 定点突变ApoE基因的方法 |
CN106399366A (zh) * | 2016-08-30 | 2017-02-15 | 中国农业大学 | 猪ApoE基因敲除打靶载体及其构建方法和应用 |
-
2018
- 2018-04-28 WO PCT/CN2018/085097 patent/WO2018196874A1/zh active Application Filing
- 2018-04-28 CN CN201880028071.9A patent/CN110691512B/zh active Active
- 2018-04-28 US US16/609,110 patent/US11882816B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050136005A1 (en) * | 1994-06-23 | 2005-06-23 | Massachusetts Institute Of Technology | Methods for modulation of cholesterol transport |
US6437215B1 (en) * | 1999-06-28 | 2002-08-20 | Massachusetts Institute Of Technology | SR-BI and ApoE knockout animals and use thereof as models for atherosclerosis and heart attack |
CN1503623A (zh) * | 2001-04-10 | 2004-06-09 | 长沙惠霖干细胞工程有限公司 | 一种构建哺乳动物克隆胚的方法 |
US20080075663A1 (en) * | 2006-06-20 | 2008-03-27 | The J. David Gladstone Institutes | Mouse Model of Chronic Heart Failure and Coronary Atherosclerosis Regression |
WO2012129198A1 (en) * | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
CN104677844A (zh) * | 2015-02-10 | 2015-06-03 | 浙江凯成生物科技有限公司 | 一种载脂蛋白e的定量测定方法、试剂及试剂盒 |
CN106148406A (zh) * | 2015-03-26 | 2016-11-23 | 中国农业大学 | 猪ApoE基因敲除载体及其构建方法与应用 |
CN106244556A (zh) * | 2016-08-29 | 2016-12-21 | 中国农业科学院北京畜牧兽医研究所 | 定点突变ApoE基因的方法 |
CN106399366A (zh) * | 2016-08-30 | 2017-02-15 | 中国农业大学 | 猪ApoE基因敲除打靶载体及其构建方法和应用 |
Non-Patent Citations (1)
Title |
---|
AYCE YESILALTAYD 等: "Loss of PDZK1 Causes Coronary Artery Occlusion and Myocardial Infarction in Paigen Diet-Fed Apolipoprotein E Deficient Mice", 《PLOS ONE》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205375A (zh) * | 2019-06-26 | 2019-09-06 | 宁夏医科大学 | 一种动脉粥样硬化诊断用分子标志物及其应用 |
CN114304064A (zh) * | 2021-12-16 | 2022-04-12 | 首都医科大学 | 一种头部畸形伴神经-运动障碍动物模型的建立方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110691512B (zh) | 2021-11-09 |
WO2018196874A1 (zh) | 2018-11-01 |
US20200077632A1 (en) | 2020-03-12 |
US11882816B2 (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Collins et al. | Mild overexpression of MeCP2 causes a progressive neurological disorder in mice | |
US7960606B2 (en) | Mouse model of chronic heart failure and coronary atherosclerosis regression | |
JP5080988B2 (ja) | 線維性疾患のためのモデルとしての遺伝子導入動物 | |
Chern et al. | Mouse models to study the pathophysiology of combined methylmalonic acidemia and homocystinuria, cblC type | |
Santander et al. | Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier | |
CN110691512B (zh) | 遗传工程化的非人类哺乳动物及其构建方法和应用 | |
KR20050040517A (ko) | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 | |
Li et al. | Engineered pigs carrying a gain-of-function NLRP3 homozygous mutation can survive to adulthood and accurately recapitulate human systemic spontaneous inflammatory responses | |
US6437215B1 (en) | SR-BI and ApoE knockout animals and use thereof as models for atherosclerosis and heart attack | |
JPWO2019067875A5 (zh) | ||
CN114317604B (zh) | 一种自发性肺动脉高压模型及构建方法 | |
Song et al. | Conditionally targeted deletion of PSEN1 leads to diastolic heart dysfunction | |
Grimes et al. | Rpl3l gene deletion in mice reduces heart weight over time | |
Aigner et al. | Genetically tailored pig models for translational biomedical research | |
JP5669055B2 (ja) | ダブルノックアウト非ヒト動物 | |
JP2012125235A (ja) | 間質性肺炎モデル及びその用途 | |
JP6650649B2 (ja) | 遺伝子改変非ヒトモデル動物 | |
JP6587091B2 (ja) | 寿命短縮化モデル非ヒト哺乳動物 | |
WO2022047758A1 (en) | Genetical disease modelling using mammals having nlrp3 mutation | |
JP2008131918A (ja) | AMPKの脱リン酸化酵素作用を持つプロテインホスファターゼ2Cε(PP2Cε)の使用。 | |
JPWO2007043589A1 (ja) | 統合失調症モデル動物 | |
Li et al. | Effect of water temperature on the recovery of spinal cord injury in zebrafish | |
CN116058335A (zh) | 一种自发强直性脊柱炎模型的构建方法和应用 | |
JP2022153749A (ja) | ベッカー型筋ジストロフィー心筋症ブタモデル。 | |
Allwood et al. | Novel roles of cardiac-derived erythropoietin in cardiac development and function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |